As public health safety measures related to COVID-19 remain and continue to restrict social gathering including public meetings and gatherings, we wanted to update you about the postponed 2020 AAADV Workshop.

We understand that many registered participants are wondering about the specific plans and hope you understand that we have been working to resolve the large number of operational details this change in plans creates, including the commitments by the US FDA and other international regulatory officials. Given the expected activities and challenges in medicine and health care that are impacting the regulatory infrastructure, the AAADV Workshop will be postponed until May 4-7, 2021.

If you have registered for the 2020 AAADV Workshop, you will have secured your admission and participation in the postponed workshop.

The mission of the AAADV Workshop remains critical to the stakeholders in anticancer drug development. We are enthusiastic about delivering the information and exchange so critical to these activities, and appreciate your commitment and support of these activities, as we navigate the COVID-19 landscape.

The Accelerating Anticancer Agent Development and Validation (AAADV) Workshop Program Committee has decided to postpone the 2020 AAADV Workshop, originally scheduled for May 5-8 at the Bethesda North Marriot Hotel and Conference Center, North Bethesda, Maryland. 

The AAADV Workshop Program Committee has been closely monitoring the domestic and worldwide developments of the COVID-19 pandemic, including the postponement of the AACR Annual Meeting. In addition, the March 17, 2020 CDC guidance recommends avoiding in-person events & no groups of people over 10, for the next 8 weeks.

While the decision to postpone the AAADV Workshop is disappointing, we recognize that the unique educational opportunities afforded by the AAADV Workshop are appreciated and valued by the cancer research community, including patients, clinicians, scientists and professionals developing anticancer products. Consequently, we are investigating options for rescheduling the Workshop, while avoiding overlap with other rescheduled meetings.

We thank all of our stakeholders for their patience and support at this time. Additional information regarding the rescheduled meeting logistics will be posted on the website and AAADV Workshop registration page and communicated widely as they are confirmed. – UPDATED 2020-03-20

17th Annual AAADV Workshop

17th Annual Workshop May 5-8, 2020, Bethesda, Maryland


Leaders in clinical and translational cancer research from academia, industry, government and nonprofit advocacy sectors convene each spring in Bethesda, Maryland, for the AAADV Workshop, a unique forum designed to speed cancer treatments to patients. This four-day, on-site interactive workshop offers a mix of small group lectures, moderated discussions, plenary lectures and facilitated case studies of successful drug applications. Participants gain valuable insights on negotiating the spectrum of successful drug development and hone their strategic planning skills with a focus on target validation and pathway identification. AAADV is the only workshop held in collaboration with the U.S. Food and Drug Administration designed specifically to help participants understand and negotiate the drug development approval process so effective cancer treatments can reach patients more quickly.


The AAADV Workshop is designed for scientists and consumer advocates with clinical trial experience interested in developing agents for the diagnosis, treatment or prevention of cancer. Individuals with limited experience in the regular aspects of oncology drug development will benefit from the knowledge of and networking with more experienced investigators and advocates.

Scholarships covering the cost of registration, travel and accommodations for the Pre-Workshop for Patient Advocate attendees are available.

Participants Will:​

• Examine the most urgent issues and meaningful trends in anticancer agent development and validation.

• Learn new approaches for diagnosing, treating and preventing cancer.

• Benefit from a mix of small group lectures, moderated discussions, facilitated case studies of successful new drug applications and plenary lectures.

• Network with researchers, regulators, patient advocates and others working on the front lines of cancer research and treatment.

Special Features

Case studies of successful new drug applications feature pharmaceutical drug development teams and U.S. Food and Drug Administration officers involved in the drug approval process. Four drugs will be presented twice over the course of the Workshop.

The AAADV Workshop In-Depth Discussion Groups offer moderated sessions on numerous topics, each presented by a panel including researchers from academia, industry and the U.S. Food and Drug Administration, as well as patient advocates, giving attendees a rare opportunity to interact with and question numerous experts in a given field of study. Attendees will choose one of five topics, presented concurrently, to attend each day.

The Core Curriculum is designed for early-career drug development investigators and covers all aspects of clinical studies: pre-clinical and clinical science, statistical structure of trials, ethical requirements and regulatory considerations. It is taught by U.S. Food and Drug Administration (FDA) medical officers and senior scientists. Core Curriculum sessions occur concurrently with AAADV Workshop morning sessions on May 5, and offer breakfast discussion groups May 5-8.

Satellite Sessions are additional meetings or presentations held the afternoon of May 8 after conclusion of the AAADV Workshop. Visit back for details and room locations. 

Executive Committee

H. Kim Lyerly, MD

Duke University

Jennifer Gao, MD

Program Committee Chair
US Food and Drug Administration

Richard Pazdur, MD

US Food and Drug Administration

Mary Scroggins, MA

International Gynecologic Cancer Society (IGCS)

Rea Blakey, MS

US Food and Drug Administration

Dianne Spillman​, BS

US Food and Drug Administration